Abstract
Background: Most drugs exert their biological and physiological effects via binding to protein targets. Although drugs are traditionally optimized against a single protein, most marketed drugs exhibit clinically relevant polypharmacology – the activity of drugs at multiple targets. The wide-spread presence of polypharmacology makes it challenging to assess the mechanisms of action of multi-target drugs. Methods: This paper first reviews approaches for discovering multi-targets of drug molecules, then discusses key characteristics of label-free cell phenotypic assays, and finally focuses on how to use these assays to assess drug polypharmacology. Results: labelfree cell phenotypic assays have ability to provide a holistic view of drug action in living cells with wide phenotype/ target/pathway coverage, and permit effective deconvolution of the action of multi-target drugs at the whole cell level. Conclusion: Label-free cell phenotypic assays hold great potential in assessing drug polypharmacology.
Keywords: label-free cell phenotypic assay, mechanism of action, multi-target screen, polypharmacology, resonant waveguide grating biosensor, electric biosensor.
Current Pharmaceutical Design
Title:Label-Free Cell Phenotypic Assays for Assessing Drug Polypharmacology
Volume: 22 Issue: 21
Author(s): Jixia Wang, Xiuli Zhang, Ye Fang and Xinmiao Liang
Affiliation:
Keywords: label-free cell phenotypic assay, mechanism of action, multi-target screen, polypharmacology, resonant waveguide grating biosensor, electric biosensor.
Abstract: Background: Most drugs exert their biological and physiological effects via binding to protein targets. Although drugs are traditionally optimized against a single protein, most marketed drugs exhibit clinically relevant polypharmacology – the activity of drugs at multiple targets. The wide-spread presence of polypharmacology makes it challenging to assess the mechanisms of action of multi-target drugs. Methods: This paper first reviews approaches for discovering multi-targets of drug molecules, then discusses key characteristics of label-free cell phenotypic assays, and finally focuses on how to use these assays to assess drug polypharmacology. Results: labelfree cell phenotypic assays have ability to provide a holistic view of drug action in living cells with wide phenotype/ target/pathway coverage, and permit effective deconvolution of the action of multi-target drugs at the whole cell level. Conclusion: Label-free cell phenotypic assays hold great potential in assessing drug polypharmacology.
Export Options
About this article
Cite this article as:
Wang Jixia, Zhang Xiuli, Fang Ye and Liang Xinmiao, Label-Free Cell Phenotypic Assays for Assessing Drug Polypharmacology, Current Pharmaceutical Design 2016; 22 (21) . https://dx.doi.org/10.2174/1381612822666160224142048
DOI https://dx.doi.org/10.2174/1381612822666160224142048 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Matrix Metalloproteinases in Inflammatory Conditions
Current Drug Targets Epigenetic Biomarkers for Risk Assessment of Particulate Matter Associated Lung Cancer
Current Drug Targets Advances in the use of MOFs for Cancer Diagnosis and Treatment: An Overview
Current Pharmaceutical Design Transcriptional Regulation of mPGES1 in Cancer: An Alternative Approach to Drug Discovery?
Current Drug Targets Interconnection of Estrogen/Testosterone Metabolism and Mevalonate Pathway in Breast and Prostate Cancers
Current Molecular Pharmacology Trichothecin from Endophytic Fungus Trichothecium sp. and its Anticancer Effect on Murine Melanoma and Breast Cancer Cell Lines
Current Biochemical Engineering (Discontinued) Development of <sup>18</sup>F-Labeled PET Probes for Imaging Cell Proliferation
Current Topics in Medicinal Chemistry ErbB Antagonists Patenting: “Playing Chess with Cancer”
Recent Patents on Biotechnology Thermosensitive Polymeric Hydrogels As Drug Delivery Systems
Current Medicinal Chemistry Peptides Targeting Angiogenesis Related Growth Factor Receptors
Current Pharmaceutical Design Melanocortins As Innovative Drugs for Ischemic Diseases and Neurodegenerative Disorders: Established Data and Perspectives
Current Medicinal Chemistry Ovarian Cancer - Angiogenesis and Targeted Therapy
Current Angiogenesis (Discontinued) Radix Stephaniae Tetrandrine: An Emerging Role for Management of Breast Cancer
Current Pharmaceutical Design Adenosine Deaminase in the Modulation of Immune System and its Potential as a Novel Target for Treatment of Inflammatory Disorders
Current Drug Targets Recent Advances on Immunosuppressive Drugs and Remyelination Enhancers for the Treatment of Multiple Sclerosis
Current Pharmaceutical Design Opioid Growth Factor and its Derivatives as Potential Non-toxic Multifunctional Anticancer and Analgesic Compounds
Current Medicinal Chemistry Actinium-225 in Targeted Alpha-Particle Therapeutic Applications
Current Radiopharmaceuticals Apixaban - Metabolism, Pharmacologic Properties and Drug Interactions
Current Drug Metabolism Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience
Current Drug Targets Proliferation of Breast Cancer Cells: Regulation, Mediators, Targets for Therapy
Anti-Cancer Agents in Medicinal Chemistry